0001708138-20-000044.txt : 20200420
0001708138-20-000044.hdr.sgml : 20200420
20200420192900
ACCESSION NUMBER: 0001708138-20-000044
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200416
FILED AS OF DATE: 20200420
DATE AS OF CHANGE: 20200420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Landry Robert E
CENTRAL INDEX KEY: 0001585160
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20803683
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-04-16
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001585160
Landry Robert E
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
EVP Finance CFO
Common Stock
2020-04-16
4
M
0
4000
272.7
A
28373
D
Common Stock
2020-04-16
4
F
0
3009
529.79
D
25364
D
Common Stock
2020-04-17
4
S
0
33
540.7
D
25331
D
Common Stock
2020-04-17
4
S
0
33
542.25
D
25298
D
Common Stock
2020-04-17
4
S
0
61
548.99
D
25237
D
Common Stock
2020-04-17
4
S
0
3
550.0
D
25234
D
Common Stock
2020-04-17
4
S
0
55
551.38
D
25179
D
Common Stock
2020-04-17
4
S
0
62
553.85
D
25117
D
Common Stock
2020-04-17
4
S
0
33
556.43
D
25084
D
Common Stock
2020-04-17
4
S
0
89
558.63
D
24995
D
Common Stock
2020-04-17
4
S
0
155
559.25
D
24840
D
Common Stock
2020-04-17
4
S
0
232
560.31
D
24608
D
Common Stock
2020-04-17
4
S
0
92
561.96
D
24516
D
Common Stock
2020-04-17
4
S
0
33
562.77
D
24483
D
Common Stock
2020-04-17
4
S
0
66
563.63
D
24417
D
Common Stock
2020-04-17
4
S
0
44
565.77
D
24373
D
Common Stock
2020-04-17
4
M
0
12500
272.7
A
36873
D
Common Stock
2020-04-17
4
F
0
9250
555.82
D
27623
D
Common Stock
2020-04-20
4
S
0
35
562.71
D
27588
D
Common Stock
2020-04-20
4
S
0
225
563.74
D
27363
D
Common Stock
2020-04-20
4
S
0
340
564.76
D
27023
D
Common Stock
2020-04-20
4
S
0
902
565.52
D
26121
D
Common Stock
2020-04-20
4
S
0
944
566.44
D
25177
D
Common Stock
2020-04-20
4
S
0
114
567.76
D
25063
D
Common Stock
2020-04-20
4
S
0
126
568.11
D
24937
D
Common Stock
2020-04-20
4
S
0
66
569.22
D
24871
D
Common Stock
2020-04-20
4
S
0
114
571.65
D
24757
D
Common Stock
2020-04-20
4
S
0
64
572.42
D
24693
D
Common Stock
2020-04-20
4
S
0
320
573.4
D
24373
D
Common Stock
200
I
By 401(k) Plan
Non-Qualified Stock Option (right to buy)
272.7
2020-04-16
4
M
0
4000
0.0
D
2023-09-09
Common Stock
4000
31500
D
Non-Qualified Stock Option (right to buy)
272.7
2020-04-17
4
M
0
12500
0.0
D
2023-09-09
Common Stock
12500
19000
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 89 shares of Company stock on April 17, 2020 at prices ranging from $558.61 to $558.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
Represents volume-weighted average price of sales of 155 shares of Company stock on April 17, 2020 at prices ranging from $559.21 to $559.39. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
Represents volume-weighted average price of sales of 232 shares of Company stock on April 17, 2020 at prices ranging from $560.02 to $560.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
Represents volume-weighted average price of sales of 92 shares of Company stock on April 17, 2020 at prices ranging from $561.92 to $561.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
Represents volume-weighted average price of sales of 66 shares of Company stock on April 17, 2020 at prices ranging from $563.39 to $563.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
Represents volume-weighted average price of sales of 225 shares of Company stock on April 20, 2020 at prices ranging from $563.56 to $563.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 340 shares of Company stock on April 20, 2020 at prices ranging from $564.14 to $564.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 902 shares of Company stock on April 20, 2020 at prices ranging from $565.05 to $565.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 944 shares of Company stock on April 20, 2020 at prices ranging from $566.01 to $566.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 126 shares of Company stock on April 20, 2020 at prices ranging from $568.10 to $568.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 66 shares of Company stock on April 20, 2020 at prices ranging from $569.10 to $569.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 64 shares of Company stock on April 20, 2020 at prices ranging from $572.19 to $572.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 320 shares of Company stock on April 20, 2020 at prices ranging from $573.01 to $573.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
The stock option award vests in four equal annual installments, commencing one year after the date of grant.
/s/**Robert E. Landry
2020-04-20